Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTNK-tPA vs rt-PA in ultra-acute ischemic stroke (≤4.5h)
CTR20210260Phase 3Completed
- Sponsor
- Guangzhou Mingkang Bioengineering
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase in ischemic stroke, sponsored by Guangzhou Mingkang Bioengineering. Started Feb 2021; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20210260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210260.